DE69938743D1 - TNF-Peptide zur Behandlung von Ödemen - Google Patents

TNF-Peptide zur Behandlung von Ödemen

Info

Publication number
DE69938743D1
DE69938743D1 DE69938743T DE69938743T DE69938743D1 DE 69938743 D1 DE69938743 D1 DE 69938743D1 DE 69938743 T DE69938743 T DE 69938743T DE 69938743 T DE69938743 T DE 69938743T DE 69938743 D1 DE69938743 D1 DE 69938743D1
Authority
DE
Germany
Prior art keywords
alpha
present
oedema
edema
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69938743T
Other languages
German (de)
English (en)
Inventor
Baetselier Patrick De
Alain Bloc
Rudolf Lucas
Lucie Fransen
Jerome Pugin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69938743D1 publication Critical patent/DE69938743D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69938743T 1998-08-14 1999-08-10 TNF-Peptide zur Behandlung von Ödemen Expired - Lifetime DE69938743D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98870180 1998-08-14
EP98870198 1998-09-18
EP98870222 1998-10-21

Publications (1)

Publication Number Publication Date
DE69938743D1 true DE69938743D1 (de) 2008-06-26

Family

ID=27239778

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69938743T Expired - Lifetime DE69938743D1 (de) 1998-08-14 1999-08-10 TNF-Peptide zur Behandlung von Ödemen
DE69937206T Expired - Lifetime DE69937206T2 (de) 1998-08-14 1999-08-10 TNF-Peptide und deren Verwendung zur Behandlung von Ödemen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69937206T Expired - Lifetime DE69937206T2 (de) 1998-08-14 1999-08-10 TNF-Peptide und deren Verwendung zur Behandlung von Ödemen

Country Status (20)

Country Link
US (2) US20030105021A1 (https=)
EP (3) EP1264599B1 (https=)
JP (1) JP4542266B2 (https=)
CN (1) CN1181886C (https=)
AT (2) ATE374039T1 (https=)
AU (1) AU764992B2 (https=)
BR (1) BR9912899A (https=)
CA (1) CA2334941C (https=)
CZ (1) CZ302862B6 (https=)
DE (2) DE69938743D1 (https=)
DK (1) DK1264599T3 (https=)
ES (1) ES2296872T3 (https=)
HU (1) HU227661B1 (https=)
IL (2) IL141064A0 (https=)
NZ (1) NZ509604A (https=)
PL (1) PL203706B1 (https=)
PT (1) PT1264599E (https=)
TR (1) TR200100338T2 (https=)
WO (1) WO2000009149A1 (https=)
ZA (1) ZA200100656B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1264599B1 (en) 1998-08-14 2007-09-26 Rudolf Lucas TNF-derived peptides for use in treating oedema
CA2575513C (en) * 2004-08-06 2014-09-16 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506151B1 (de) 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
AT507953B1 (de) 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) * 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
PL2397151T3 (pl) * 2010-06-21 2015-10-30 Apeptico Forschung & Entwicklung Gmbh Leczenie powikłań naczyniowych cukrzycy
US11161881B2 (en) * 2010-11-18 2021-11-02 Apeptico Forschung Und Entwicklung Gmbh Composition comprising a peptide and an inhibitor of viral neuraminidase
AT510585B1 (de) 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
EP2679239A1 (de) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
US20160143266A1 (en) * 2013-04-23 2016-05-26 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical Composition Comprising a Cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
US10925924B2 (en) 2014-03-18 2021-02-23 Apeptico Forschung Und Entwicklung Gmbh Dry-powder peptide medicament
CN110613838A (zh) * 2018-06-19 2019-12-27 姜石松 增强细胞通透性的多肽及其应用
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN115461356A (zh) 2020-05-08 2022-12-09 阿佩普蒂科研究和开发有限责任公司 用于预防或治疗covid-19的肽

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE384179C (de) * 1921-04-07 1923-10-27 Ludwig Weil Dr Laufrad fuer Kreiselpumpen und -geblaese
DE3841759A1 (de) * 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
WO1994018325A1 (en) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
EP1264599B1 (en) 1998-08-14 2007-09-26 Rudolf Lucas TNF-derived peptides for use in treating oedema

Also Published As

Publication number Publication date
IL141064A0 (en) 2002-02-10
US20030105021A1 (en) 2003-06-05
CZ302862B6 (cs) 2011-12-21
CN1312724A (zh) 2001-09-12
AU5620999A (en) 2000-03-06
HK1051805A1 (en) 2003-08-22
IL141064A (en) 2009-09-01
ATE395072T1 (de) 2008-05-15
ZA200100656B (en) 2005-06-29
PT1264599E (pt) 2008-01-07
HUP0103117A2 (hu) 2001-12-28
CZ2001538A3 (cs) 2001-08-15
EP1247531A2 (en) 2002-10-09
ES2296872T3 (es) 2008-05-01
EP1247531A3 (en) 2002-12-18
EP1264599A1 (en) 2002-12-11
NZ509604A (en) 2003-05-30
CA2334941C (en) 2011-08-09
DK1264599T3 (da) 2008-02-04
CA2334941A1 (en) 2000-02-24
ATE374039T1 (de) 2007-10-15
WO2000009149A1 (en) 2000-02-24
DE69937206T2 (de) 2008-06-19
EP1264599B1 (en) 2007-09-26
PL345997A1 (en) 2002-01-14
DE69937206D1 (de) 2007-11-08
EP1105152A1 (en) 2001-06-13
HU227661B1 (hu) 2011-10-28
AU764992B2 (en) 2003-09-04
US7258861B2 (en) 2007-08-21
JP2002522508A (ja) 2002-07-23
EP1247531B1 (en) 2008-05-14
PL203706B1 (pl) 2009-11-30
CN1181886C (zh) 2004-12-29
US20030185791A1 (en) 2003-10-02
HUP0103117A3 (en) 2004-03-01
BR9912899A (pt) 2001-05-08
JP4542266B2 (ja) 2010-09-08
TR200100338T2 (tr) 2001-12-21

Similar Documents

Publication Publication Date Title
DE69938743D1 (de) TNF-Peptide zur Behandlung von Ödemen
EA200400632A1 (ru) Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
EA200400205A1 (ru) Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
EA199900778A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ИСПОЛЬЗОВАНИЕ ДЛЯ ИНГИБИРОВАНИЯ β-АМИЛОИДНОГО ПЕПТИДА
DK0397420T3 (da) Enzymatisk fjernelse af en aminoterminal proteinsekvens
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
GEP20043407B (en) Method of Inhibiting Amyloid Protein Aggregation and Imaging Amyloid Deposits Using Isoindoline Derivatives
ATE285224T1 (de) Methode zur prävention und behandlung von dehnungsstreifen (striae distensae) und deren verwendung in dermatologie
DE69904511D1 (de) Proteinmaterial mit verlangsamtem verdaungsablauf und deren verwendung
DE60217326D1 (de) Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung
ATE421329T1 (de) Verwendung von aplidine zur behandlung von kardiovaskulären erkrankungen
ATE377026T1 (de) Behandlung von fettleibigkeit
IS2518B (is) Lífvirk peptíð, not fyrir þau og vinnsla þeirra
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
DE69329899D1 (de) Behandlung von tropikalischer spastischer Paresis mit Peptide T
DE602004016834D1 (de) Zusammensetzung zur vermeidung und behandlung von cellulitis
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE251631T1 (de) Dipohosphonsäuresalze für die behandlung von osteoporose
ATE310091T1 (de) Carboxypeptidasen aus aspergillus oryzae und diese kodierende nukleinsäuren
DE3786456D1 (de) Kombinationen von nekrose-tumor-faktoren und entzuendungshemmenden mitteln fuer die behandlung von boesartigen und nicht boesartigen erkrankungen.
DE69526972D1 (de) Verwendung von Gabapentin in der Behandlung vonAngst - und Panikstörungen
DE60104695D1 (de) Zusammensetzungen aus aminosäuren zur behandlung von herzinsuffizienz
ATE342352T1 (de) Entwurf und verwendung von verbesserten zink- chelatbildenden peptiden zur regulation von matrix-metalloproteinasen
ATE181240T1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen
DE50001730D1 (de) Gemisch zur behandlung von abfallmaterial

Legal Events

Date Code Title Description
8364 No opposition during term of opposition